A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Primacor IV Side Effects, and Drug Interactions - Milrinone
Primacor IV Side Effects, and Drug Interactions - Milrinone
SIDE EFFECTS
Cardiovascular Effects
In patients receiving PRIMACOR in Phase II and III clinical
trials, ventricular arrhythmias were reported in 12.1%; ventricular
ectopic activity, 8.5%;
nonsustained ventricular
tachycardia, 2.8%;
sustained ventricular tachycardia, 1% and ventricular
fibrillation, 0.2%
(2 patients experienced more than one type
of arrhythmia). Holter recordings demonstrated that in some patients
injection of PRIMACOR
increased ventricular
ectopy, including nonsustained ventricular
tachycardia. Life-threatening arrhythmias were infrequent and when
present have been associated
with certain underlying factors such
as preexisting arrhythmias, metabolic abnormalities (e.g. hypokalemia),
abnormal digoxin
levels and catheter
insertion. PRIMACOR was not shown to be arrhythmogenic in an electrophysiology
study. Supraventricular arrhythmias were reported in 3.8% of the
patients receiving PRIMACOR. The incidence of both supraventricular
and ventricular
arrhythmias has not been related to the dose
or plasma milrinone concentration.
Other cardiovascular
adverse reactions include hypotension,
2.9% and angina/chest pain,
1.2%. In the post marketing experience, there have been rare cases of "torsades de pointes" reported.
CNS Effects
Headaches, usually mild to moderate in severity, have been reported
in 2.9% of patients receiving PRIMACOR.
Other Effects
Other adverse reactions reported, but not definitely related to
the administration of PRIMACOR include hypokalemia,
0.6%; tremor, 0.4%; and
thrombocytopenia, 0.49%.
Isolated spontaneous reports of bronchospasm and anaphylactic shock have been received; and in the post-marketing experience, liver function test abnormalities and skin reactions such as rash have been reported.
DRUG INTERACTIONS
No untoward clinical
manifestations have been observed in limited experience with patients
in whom PRIMACOR was used concurrently with the following drugs:
digitalis glycosides;
lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate,
nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide,
spironolactone; captopril; heparin, warfarin, diazepam, insulin;
and potassium supplements.
Chemical Interactions
There is an immediate
chemical interaction
which is evidenced by the formation of a precipitate
when furosemide is
injected into an intravenous
line of an infusion
of PRIMACOR. Therefore, furosemide
should not be administered in intravenous
lines containing PRIMACOR.
top
